NASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free STOK Stock Alerts $11.48 -0.53 (-4.41%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$11.01▼$12.2450-Day Range$5.80▼$14.1752-Week Range$3.35▼$16.40Volume753,363 shsAverage Volume884,226 shsMarket Capitalization$598.34 millionP/E RatioN/ADividend YieldN/APrice Target$20.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Stoke Therapeutics alerts: Email Address Stoke Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside79.2% Upside$20.57 Price TargetShort InterestBearish15.94% of Shares Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.02Based on 35 Articles This WeekInsider TradingSelling Shares$41.94 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.28) to ($2.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.05 out of 5 starsMedical Sector176th out of 921 stocksPharmaceutical Preparations Industry67th out of 428 stocks 4.4 Analyst's Opinion Consensus RatingStoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageStoke Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Stoke Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.94% of the outstanding shares of Stoke Therapeutics have been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 50.27%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreStoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Stoke Therapeutics is -0.59. Previous Next 1.7 News and Social Media Coverage News SentimentStoke Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 35 news articles for Stoke Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for STOK on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,935,115.00 in company stock.Percentage Held by Insiders11.30% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Stoke Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.28) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -4.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -4.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Stoke Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here About Stoke Therapeutics Stock (NASDAQ:STOK)Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Read More STOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STOK Stock News HeadlinesApril 19, 2024 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Major Shareholder Sells $41,760,000.00 in StockMay 11, 2024 | americanbankingnews.comFY2024 EPS Estimates for Stoke Therapeutics, Inc. (NASDAQ:STOK) Increased by HC WainwrightMay 11, 2024 | Crypto 101 Media (Ad)Elon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.May 10, 2024 | americanbankingnews.comHC Wainwright Equities Analysts Reduce Earnings Estimates for Stoke Therapeutics, Inc. (NASDAQ:STOK)May 9, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Stoke Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:STOK)May 9, 2024 | americanbankingnews.comStoke Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.53) Per Share, Wedbush Forecasts (NASDAQ:STOK)May 9, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by HC WainwrightMay 9, 2024 | americanbankingnews.comCanaccord Genuity Group Lowers Stoke Therapeutics (NASDAQ:STOK) Price Target to $20.00May 11, 2024 | Crypto 101 Media (Ad)Elon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Stoke Therapeutics Amid Strong Pipeline Prospects and Financial StabilityMay 8, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by Needham & Company LLCMay 7, 2024 | finance.yahoo.comStoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...May 7, 2024 | markets.businessinsider.comBuy Rating for Stoke Therapeutics with Adjusted Price Target Amid Regulatory and Developmental ProgressMay 7, 2024 | finance.yahoo.comStoke Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 6, 2024 | investorplace.comSTOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | markets.businessinsider.comStoke Therapeutics Inc Q1 Loss increases, but beats estimatesMay 6, 2024 | businesswire.comStoke Therapeutics Reports First Quarter Financial Results and Provides Business UpdatesMay 3, 2024 | msn.comStoke City latest as boss outlines plan for out of contract starsMay 3, 2024 | msn.comJCB to shut Stoke-on-Trent warehouse as up to 200 workers face uncertain futureMay 1, 2024 | msn.comLiam Manning drops Matty James contract hint as Bristol City captain is ruled out of Stoke clashMay 1, 2024 | msn.comStoke City skeleton squad for next season as starting gun fires for summer transfer windowMay 1, 2024 | msn.comCatalogue of 131 Championship free agents as Stoke City prepare for summer transfer spreeMay 1, 2024 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 1, 2024 | uk.news.yahoo.comChampionship 2024/25 line-up, final day permutations, points deduction and renewed rivalries for Stoke CityApril 30, 2024 | msn.comStoke City youngster confirms exit with classy messageApril 30, 2024 | uk.news.yahoo.comRoadworks on this busy Stoke-on-Trent route spark rush-hour 'chaos'April 30, 2024 | msn.comHonest Ben Wilmot opens up on Stoke City season and who will succeed him as player of the yearSee More Headlines Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/11/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:STOK CUSIPN/A CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$20.57 High Stock Price Target$35.00 Low Stock Price Target$13.00 Potential Upside/Downside+79.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,700,000.00 Net MarginsN/A Pretax Margin-1,192.47% Return on Equity-62.28% Return on Assets-44.90% Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio6.99 Sales & Book Value Annual Sales$8.78 million Price / Sales68.15 Cash FlowN/A Price / Cash FlowN/A Book Value$3.57 per share Price / Book3.22Miscellaneous Outstanding Shares52,120,000Free Float46,229,000Market Cap$598.34 million OptionableOptionable Beta0.82 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Edward M. Kaye M.D. (Age 75)Ph.D., CEO & Director Comp: $931.21kDr. Adrian R. Krainer Ph.D. (Age 65)Co-Founder & Independent Director Comp: $44kMr. Stephen J. Tulipano CPA (Age 65)MBA, Chief Financial Officer Comp: $619.09kDr. Barry S. Ticho FACC (Age 63)M.D., Ph.D., Chief Medical Officer Comp: $688.83kMs. Isabel Aznarez Ph.D. (Age 51)Co-Founder & Group VP of Discovery Research Dr. Huw M. Nash Ph.D. (Age 57)COO & Chief Business Officer Comp: $429.67kMr. Eric RojasHead of Investor RelationsMr. Jonathan Allan J.D. (Age 34)Corporate Secretary & General Counsel Ms. Dawn Kalmar (Age 46)Chief Communications Officer Ms. Joan WoodChief Human Resources OfficerMore ExecutivesKey CompetitorsGH ResearchNASDAQ:GHRSOlema PharmaceuticalsNASDAQ:OLMACalliditas Therapeutics AB (publ)NASDAQ:CALTZymeworksNYSE:ZYMEPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 67,052 shares on 5/10/2024Ownership: 3.292%State Board of Administration of Florida Retirement SystemBought 10,473 shares on 5/9/2024Ownership: 0.020%Susquehanna Portfolio Strategies LLCSold 1,684 shares on 5/7/2024Ownership: 0.083%SG Americas Securities LLCSold 5,443 shares on 5/7/2024Ownership: 0.019%GSA Capital Partners LLPSold 4,599 shares on 5/3/2024Ownership: 0.187%View All Insider TransactionsView All Institutional Transactions STOK Stock Analysis - Frequently Asked Questions Should I buy or sell Stoke Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STOK shares. View STOK analyst ratings or view top-rated stocks. What is Stoke Therapeutics' stock price target for 2024? 8 brokers have issued 12 month price objectives for Stoke Therapeutics' stock. Their STOK share price targets range from $13.00 to $35.00. On average, they anticipate the company's share price to reach $20.57 in the next twelve months. This suggests a possible upside of 79.2% from the stock's current price. View analysts price targets for STOK or view top-rated stocks among Wall Street analysts. How have STOK shares performed in 2024? Stoke Therapeutics' stock was trading at $5.26 on January 1st, 2024. Since then, STOK stock has increased by 118.3% and is now trading at $11.48. View the best growth stocks for 2024 here. When is Stoke Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our STOK earnings forecast. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its quarterly earnings data on Monday, March, 25th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.02. The business earned $2.80 million during the quarter, compared to the consensus estimate of $3.70 million. What ETFs hold Stoke Therapeutics' stock? ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Morningstar US Small Growth (MSGR).WisdomTree BioRevolution Fund (WDNA). What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA). When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Stoke Therapeutics' major shareholders? Stoke Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.29%), GSA Capital Partners LLP (0.19%), Mirae Asset Global Investments Co. Ltd. (0.17%), Susquehanna Portfolio Strategies LLC (0.08%), Seven Grand Managers LLC (0.06%) and Chase Investment Counsel Corp (0.04%). Insiders that own company stock include Barry Ticho, Edward M Md Kaye, Huw M Nash, Jonathan Allan, Skorpios Trust and Stephen J Tulipano. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:STOK) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCollapse of the Petrodollar Colonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
